Alnylam Pharmaceuticals
ALNY
#1121
Rank
HK$164.51 B
Marketcap
HK$1,228
Share price
0.43%
Change (1 day)
-64.24%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -HK$32.19

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is HK$155.37. In 2022 the company made an earnings per share (EPS) of -HK$72.86 a decrease over its 2021 EPS that were of -HK$56.47.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-HK$32.19-55.82%
2022-HK$72.8629.03%
2021-HK$56.47-3.36%
2020-HK$58.43-8.48%
2019-HK$63.847.67%
2018-HK$59.2939.74%
2017-HK$42.4312.94%
2016-HK$37.5738.84%
2015-HK$27.06-32.88%
2014-HK$40.31259.44%
2013-HK$11.22-31.25%
2012-HK$16.3152.94%
2011-HK$10.6730.77%
2010-HK$8.16-8.77%
2009-HK$8.9478.13%
2008-HK$5.02-70.78%
2007-HK$17.1899.09%
2006-HK$8.63-43.88%
2005-HK$15.37-82.33%
2004-HK$87.00-59.23%
2003-HK$213.41

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
HK$41.18-73.50%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$14.92-90.39%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
HK$328.70 111.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-HK$20.63-113.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-HK$5.73-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-HK$0.71-100.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$4.94-96.82%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-HK$26.12-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA